作者
Feiyan Long,Jinyu Li,Yanru Kang,Yanjing Li,Tian Ma,Junbai Ma,Jian Liu,Ping Yang,Shuai Luo,Lina Zhang,Xiaoxia Zhang,Shaoqi Yang,Hao Wang
摘要
Objective Alcoholic liver disease (ALD) resulting from sustained excessive alcohol consumption is a leading global cause of chronic liver injury, characterized by persistent hepatic inflammation and profound gut microbiota dysbiosis. Despite its substantial burden of morbidity and mortality, no effective therapeutic interventions are currently available beyond alcohol abstinence. Therefore, this study aims to investigate the ameliorative effects of probiotic strains with ethanol-metabolizing capacity, administered either alone or in combination with beneificial microbiota-derived metabolite sodium butyrate (NaB) on ALD. Methods Probiotic strains representing capable of ethanol metabolism were isolated, purified, and identified from individuals with long-term alcohol consumption but without liver injury. These strains were then administered individually or in combination with NaB in antibiotic cocktail (ABX)-treated C57BL/6J mice fed an ethanol-containing Lieber-DeCarli liquid diet. After 6 weeks of treatment, mice were euthanized and relevant parameters were investigated. Results We isolated 14 ethanol-metabolizing bacterial strains from fecal samples of healthy individuals with chronic heavy alcohol consumption. Intriguingly, five of the 14 candidate probiotic strains, namely ML, MN, T2, T23, and TF, exhibited significantly enhanced growth during in vitro co-culture with NaB. Administration of each of these strains markedly attenuated hepatic steatosis in ALD mice, as evidenced by reduced serum concentrations of triglycerides (TG) and low-density lipoprotein (LDL), alonged with decreased activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Furthermore, these probiotics suppressed inflammation by reducing pro-inflammatory tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-1β, and elevating anti-inflammatory IL-10. Importantly, the stranis separately improved ethanol clearance via enhancing both activity and expression of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Moreover, the combination of each strain of these five strains with NaB yielded significantly greater improvements across ALD-related pathological parameters than those in probiotic monotherapy, demonstrating a robust synergistic therapeutic effect. Metagenomic analysis further revealed that these strains were markedly enriched in metabolic pathways including central to glycolysis, pyruvate metabolism, and the glyoxylate cycle. Conclusion This study provides a novel synbiotics of five probiotic strains in combination with NaB possessing ethanol-metabolizing capacity, which may contribute to potential preventive and therapeutic agents for ALD.